Foresite Capital Management IV’s Xenon Pharmaceuticals XENE Stock Holding History

Foresite Capital Management IV’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.66M	Hold	160,000	–	–	3.33%	5
2026 Q1	$9.3M	Hold	160,000	–	–	3.92%	6
2025 Q4	$7.17M	Hold	160,000	–	–	3.12%	6
2025 Q3	$6.42M	Hold	160,000	–	–	3.52%	5
2025 Q2	$5.01M	Buy	+160,000	New	+$5.22M	4.05%	4
2018 Q4	–	Sell	-385,714	Closed	-$5.09M	–	24
2018 Q3	$5.09M	Buy	+385,714	New	+$4.47M	1.67%	15

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Foresite Capital Management IV's XENE Position: Q2 2026 in Review

Foresite Capital Management IV held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 160,000 shares worth $9.66M. The position accounts for 3.33% of the portfolio, ranked #5.

Foresite Capital Management IV first reported a position in XENE in Q3 2018 and has held it in 6 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Foresite Capital Management IV held 160,000 shares of Xenon Pharmaceuticals worth $9.66M as of Q2 2026.
Foresite Capital Management IV left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up 3.33% of Foresite Capital Management IV's portfolio in Q2 2026, its #5 holding.
Foresite Capital Management IV first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 6 quarters since.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Foresite Capital Management IV's 13F filing for Q2 2026, filed 14 Aug 2026.